News

How Amgen’s latest earnings event sets the stage for investors Amgen (AMGN) just released its second quarter 2026 results, reporting revenue of US$10.05b and net income of US$2.38b, alongside updated full year guidance that gives investors fresh numbers to work with. For the first half of 2026, Amgen reported revenue of US$18.67b and net income of US$4.19b. Basic earnings per share from continuing operations were US$7.77, with diluted EPS at US$7.71 for the period. The company now expects...

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

Amgen (NasdaqGS:AMGN) has reported a major cybersecurity breach that exposed sensitive patient health information. At the same time, regulators are reviewing the clinical data supporting its rare inflammatory disease drug Tavneos, following the retraction of a pivotal publication. Together, the data breach and questions over Tavneos data raise regulatory, reputational, and operational risks for Amgen. Amgen is a large biopharmaceutical company with a broad portfolio of therapies, including...

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amgen (NASDAQ:AMGN) reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spen

Amgen (AMGN) delivered earnings and revenue surprises of +12.32% and +6.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.5% year on year to $10.05 billion. The company’s full-year revenue guidance of $38.8 billion at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $6.29 per share was 12% above analysts’ consensus estimates.

The biotechnology company now expects full-year revenue between $38.2 billion and $39.4 billion, but said it was halting the development of a potential obesity treatment currently in a phase 1 study.

Amgen smashed Wall Street's second-quarter expectations late Tuesday, delivering double-digit sales growth for nearly two dozen products.

BMY vs. AMGN: Which Stock Is the Better Value Option?

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora

Wall Street futures pointed moderately higher pre-bell Tuesday after software giant Palantir Technol

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

Amgen is investigating the extent of this breach, as preliminary findings reveal that it has exposed private patient and proprietary information.

The monthly jobs report comes out Friday. Before that, Elon Musk’s SpaceX will post its first earnings report as a listed company. Also reporting: Walt Disney; tech companies Palantir and Advanced Micro Devices; ride-sharing firms Uber and Lyft; private-equity firms Apollo, Carlyle and TPG; and fast-food chains McDonald's and Wendy’s.

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.

Here is a way to get paid a meaningful income now on your Eli Lilly shares, income you keep no matter what the stock does, in exchange for agreeing to sell at a price above today's if it climbs there.

Besides Wall Street's top-and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

Amgen has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Amgen stock has nearly doubled investors' money over the past five years, yet current checks suggest a mixed picture where the Discounted Cash Flow (DCF) intrinsic value points to meaningful upside while market multiples look closer to fair. Amgen has delivered a 93.9% return over five years, which puts more focus on whether the current share price still leaves room relative to intrinsic value estimates. Confidence around Amgen's portfolio of established and late stage products can support...

In the closing of the recent trading day, Amgen (AMGN) stood at $387.42, denoting a -1.44% move from the preceding trading day.

EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will this pharma company become a new leader in the weight loss market?

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on where the market's momentum actually lives.

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.